What Does GammaDelta Therapeutics Do?

Total employees5
HeadquartersLondon
Founded2016

GammaDelta Therapeutics, a clinical-stage biotechnology company and part of Takeda, is at the forefront of discovering and developing allogeneic immunotherapies. Their innovative approach leverages the unique properties of gamma delta (γδ) T cells to target cancer and other diseases. The company focuses on advancing its pipeline of γδ T cell-based candidates to provide novel treatment options for patients with high unmet medical needs. Their research aims to harness the power of these specialized immune cells to create 'off-the-shelf' therapies.

Where Is GammaDelta Therapeutics's Headquarters?

HQ Function

The headquarters serves as the central hub for research and development, corporate operations, and strategic leadership for GammaDelta Therapeutics' pioneering work in γδ T cell therapies.

Notable Features:

Located in White City Place, a prominent campus for life sciences, technology, and creative industries, offering state-of-the-art laboratory and office facilities.

Work Culture:

The work culture at GammaDelta Therapeutics, now part of Takeda, is expected to be highly scientific, innovative, and collaborative, focusing on cutting-edge research in cell therapy. It likely combines an agile biotech spirit with the resources and structure of a large pharmaceutical company, emphasizing rigor, patient-focus, and teamwork.

HQ Significance:

The London HQ is strategically located in White City Place, a leading life sciences hub, providing access to world-class talent, research institutions, and a collaborative ecosystem. Its integration within Takeda further enhances its significance by connecting it to global R&D and clinical development capabilities.

Values Reflected in HQ: The state-of-the-art facilities in a dynamic innovation district reflect GammaDelta's commitment to pioneering science, research excellence, and collaboration within the broader life sciences community.

Location:

As a Takeda company, GammaDelta Therapeutics' innovative research in gamma delta T cell therapies contributes to Takeda's global oncology pipeline. Their work supports the development of potential treatments for patients worldwide, leveraging Takeda's extensive global network for clinical development, manufacturing, and future commercialization. While its primary research and operational hub is in London, its impact and collaborations are global through the Takeda infrastructure.

Street Address:

WestWorks Building, White City Place, 195 Wood Lane

City:

London

State/Province:

England

Country:

United Kingdom

Where Else Does GammaDelta Therapeutics Operate Around the World?

No additional office locations available.

Buying Intent Signals for GammaDelta Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading GammaDelta Therapeutics? Meet the Executive Team

As of April 2025, GammaDelta Therapeutics' leadership includes:

Rajiv Kaul - Head, Gamma Delta T Cell Therapy, Takeda | CEO, GammaDelta Therapeutics (a Takeda Company)
Mike Roberts, PhD - VP, Head Of Research at GammaDelta Therapeutics, A Takeda Company
Paolo Paoletti, M.D. - President, Gamma Delta T Cell Unit of Takeda (Former CEO of GammaDelta Therapeutics)

Who's Investing in GammaDelta Therapeutics?

GammaDelta Therapeutics has been backed by several prominent investors over the years, including:

Takeda (Current Parent Company)
Abingworth
Medicxi Ventures
Claris Ventures
IP Group Plc
Parkinson's UK (via the Parkinson's Virtual Biotech)

What Leadership Changes Has GammaDelta Therapeutics Seen Recently?

Hire0
Exits0

Following its acquisition and integration into Takeda in late 2022, GammaDelta Therapeutics' leadership structure has evolved. Key leadership roles for the gamma delta T cell programs are now embedded within Takeda's broader R&D and oncology organization. No major distinct GammaDelta Therapeutics C-level executive hires or exits have been publicly announced in the last 12 months (May 2023 - May 2024).

What Technology (Tech Stack) Is Used byGammaDelta Therapeutics?

Discover the tools GammaDelta Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

GammaDelta Therapeutics Email Formats and Examples

Common email formats for GammaDelta Therapeutics likely follow standard professional patterns. Given its domain gammadeltatx.com, a probable format would be combining first name and last name.

firstname.lastname@gammadeltatx.com

Format

jane.doe@gammadeltatx.com

Example

75%

Success rate

What's the Latest News About GammaDelta Therapeutics?

Takeda PharmaceuticalsNovember 9, 2023

Takeda Highlights Positive Phase 1 Data for GDX012, an Investigational Gamma Delta (γδ) T-Cell Therapy, at ASH 2023

Takeda presented positive initial data from the Phase 1 clinical trial of GDX012, an allogeneic, variable delta 1 (Vδ1) gamma-delta (γδ) T-cell therapy, in patients with relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). GDX012 originated from GammaDelta Therapeutics' platform....more

Fierce BiotechNovember 9, 2023

Takeda's gamma-delta T-cell therapy, nabbed in $100M buyout, posts early Ph1 data in AML, MDS

Fierce Biotech reported on Takeda's presentation of Phase 1 data for GDX012, a gamma-delta T-cell therapy acquired through the GammaDelta Therapeutics buyout. The therapy showed early signs of clinical activity and a manageable safety profile in treating acute myeloid leukemia and myelodysplastic syndromes....more

Takeda PharmaceuticalsOctober 4, 2022

Takeda Completes Acquisition of GammaDelta Therapeutics

Takeda announced the successful completion of its acquisition of GammaDelta Therapeutics Ltd., a company focused on exploiting the unique properties of gamma delta (γδ) T cells for immunotherapy. This acquisition aimed to further accelerate the development of Takeda’s novel immuno-oncology portfolio....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including GammaDelta Therapeutics, are just a search away.